A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent System) in the Treatment of Patients With Coronary Heart Disease
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Registrational; Therapeutic Use
- Acronyms DESSOLVE-C
- Sponsors Micell Technologies
- 29 Nov 2017 Planned End Date changed from 1 Apr 2022 to 1 Nov 2022.
- 29 Nov 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Nov 2018.
- 29 Nov 2017 Status changed from recruiting to active, no longer recruiting.